PremiumCompany AnnouncementsInhibrx Biosciences Secures $150M Loan for Growth
3M ago
Inhibrx prevails in trade secret case with I-Mab
Premium
The Fly
Inhibrx prevails in trade secret case with I-Mab
5M ago
Inhibrx management to meet virtually with Jefferies
Premium
The Fly
Inhibrx management to meet virtually with Jefferies
6M ago
Inhibrx files to sell 2.45M shares of common stock for holders
PremiumThe FlyInhibrx files to sell 2.45M shares of common stock for holders
10M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
10M ago
Inhibrx’s Strategic Financial Moves and Corporate Restructuring
Premium
Company Announcements
Inhibrx’s Strategic Financial Moves and Corporate Restructuring
10M ago
Inhibrx reports Q4 EPS ($1.73), consensus ($1.04)
PremiumThe FlyInhibrx reports Q4 EPS ($1.73), consensus ($1.04)
1y ago
Inhibrx Announces Execution of Merger Agreement
Premium
Market News
Inhibrx Announces Execution of Merger Agreement
1y ago
Inhibrx Announces Merger and Spin-Off Agreements with Aventis
Premium
Market News
Inhibrx Announces Merger and Spin-Off Agreements with Aventis
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100